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A B S T R A C T
Tuberculous meningoencephalitis (TBM) is a rare and serious, often fatal presentation of active tuberculosis and
account for about 1% of cases. Early diagnosis and prompt treatment of TBM is essential to reduce morbidity and mor-
tality. Here, we report a case of TBM in 60-year-old man. TBM was considered on the basis of clinical presentation, labo-
ratory findings (hyponatraemia), cerebrospinal fluid studies, radiological findings (hydrocephalus on multi-slice com-
puted tomography), and history of orchiepididymitis of unknown origin one year earlier, together with information that
the patient originated from Kosovo where incidence of tuberculosis is still high. Mycobacterium tuberculosis was cul-
tured from cerebrospinal fluid on Lowenstein-Jensen medium confirming diagnosis of TBM. Subsequently, acid-fast ba-
cilli (AFB) staining on samples obtained after orchiectomy a year ago was performed, revealing AFB. Anti-tuberculosis
therapy is still in course. This is the second case of tuberculous meningoencephalitis with the same disease pattern (i.e.
tuberculous orchiepididymitis – meningoencephalitis) in our Department, and this fact was crucial for the presumptive
diagnosis and urgent treatment of TBM. The former case was described five years ago.
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Introduction
Central nervous system (CNS) disease caused by My-
cobacterium tuberculosis is an uncommon yet higly dev-
astating manifestation of tuberculosis. CNS tuberculosis
(TB) account for approximately 1% of all cases of tuber-
culosis, carries a high motality and a distressing lavel of
neurological morbidity1. Early diagnosis of CNS TB is
necessary for appropiate tretment to reduce this morbid-
ity and mortality2. Mycobacterium tuberculosis infection
is prevalent in more than 2 billion people worldwide,
with about 15 million of these individuals with active
infection3,4. Tuberculosis remains a worldwide burden,
with a large majority of new active tuberculosis cases oc-
curring in underdeveloped and developing countries4. In
80% of new tuberculosis cases, demographic factor such
as poverty, crowding, malnutrition, and a compromised
immune system play a major role in the worldwide epi-
demic, while the remaining 20% of tuberculosis cases are
associated with HIV in Sub-Saharan Africa5,6.
Here we report a case of CNS TB in an immunocom-
promised male.
Case Report
A 60-year male, originated from Kosovo, with dilata-
tive cardiomiopathia and chronic liver disease, was ad-
mitted to the Nephrology unit with a slight fever, cephalea,
malaise and signs of chronic renal failure. In anamnestic
data, the patient mentioned orchiepidydimitis of un-
known origin one year back when underwent right side
orchiectomy. Laboratory on admission: CRP 83.5 mg/L,
ESR 112 mm/h, RBCs 3.02 ´ 1012/L, Hb 86 g/L, WBCs 6.2
´ 109/L, platelets 279 ´ 109/L, urea 8.2 mmol/L, creatinine
191 mmol/L, Na 127 mmol/L, bilirubine 10 mmol/L, AST
37 IU/L, ALT 45 IU/L, AP 191 IU/L, GGT 274 IU/L. A
chest radiogram showed some degree of miopatic and en-
larged cardiac configuration but without pathological
inflammation. During eight hospital days, the patient
became confused, lethargic with sphincter dysfunction.
Multi-slice computed tomography (MSCT) of the brain
showed normotensive hydrocephalus (Figure 1). Physical
examination revealed a stiff neck and urgent lumbal
puncture was performed. Cerebrospinal fluid (CSF) re-
vealed: L 59´106/L (neutrophils 87, lymphocytes 7, mo-
nocytes 4 and basophiles 2%), glucose level 1.6 mmol/L, a
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total proteini 0.56 g/L, lactate 3.47 mmol/L, chloride 102
mmol/L.
On the basis of clinical presentation, epidemiological
data, past medical history of orchiepididymitis, CSF find-
ings, hyponatraemia and hydrocephalus, the diagnosis of
tuberculous meningoencephalitis was considered. Prompt
treatment with four first-line anti-tuberculosis drugs
was initiated. Mycobacterium tuberculosis was cultured
from cerebrospinal fluid on Lowenstein-Jensen medium
confirming diagnosis of TB CNS. Subsequently, acid-fast
bacilli (AFB) staining on samples obtained after orchiec-
tomy a year ago was performed, revealing AFB. Clinical
course thereafter showed gradual but constant improve-
ment in clinical, laboratory and CSF parameters. Anti-
-tuberculosis therapy is still in course.
Discussion
Central nervous system disease caused by Mycobacte-
rium tuberculosis is an uncommon manifestation of tu-
berculosis, which was universally fatal in the era before
anti-tuberculosis therapy. Due to its relative rarity and
the protean nature of the symptoms, tuberculosis of the
CNS remains a formidable diagnostic challenge7. In the
largest prospective epidemiological study on CNS tuber-
culosis, the chance of developing CNS tuberculosis was
1.0% among 82.764 tuberculosis cases from 1970 to 2001
in a Canadian cohort8. In Kosovo, the incidence of TB
was decreased but is still high9,10. Both children and
HIV-coinfected patients are at high risk for developing
CNS tuberculosis11,12. Other risk factors include malnu-
trition and recent measles in children, alcoholism, malig-
nancies, and use of immunosuppressive agents in adults13–15.
TB meningitis is the most common cause of chronic men-
ingitis, with clinical presentation often consisting of a
subacute febrile illness with generalized neurological
syndrome. CNS TBC has the highest mortality rate (20%
to 50%) among all forms of TB, and it is associated with
more serious complications and sequelae.
The pathogenesis involves establishment of tubercu-
lous foci in the brain or meninges, usually from primary
infection or reactivation infection. The foci progress and
rupture into the subarachnoid space, thus seeding infec-
tion into the central nervous system17. The haemato-
genous seeding of M. tuberculosis occurs most frequently
in regions of the body that are highly oxygenated, includ-
ing the brain18.
Clinical signs of patients presenting with TB meningi-
tis can be easily assessed for severity based on modifica-
tions of the Medical Research Council staging system
which has been shown in numerous series to have con-
siderable prognostic value19. The classical staging system
is as follows: stage I is fully conscious and no focal deficit;
stage II is conscious but with inattention, confusion,
lethargy, and focal neurological signs such as cranial
nerve palsies; and stage III is stuporous or comatose,
multiple cranial nerve palsies, or complete hemiparesis
or paralysis. A more contemporary modification of the
staging system defines grade I as alert and oriented with-
out focal neurological deficits, grade II as a Glasgow
coma score of 11 to 14 or 15 with focal neurological defi-
cits, and grade III as a Glasgow coma score of 10 or less
with or without focal neurological deficits20,21.
Consequence of TB meningitis are hydrocephalus and
development of vasculitis in the vessels of the circle of
Willis, the vertebrobasilar system, and the perforation
branches of the middle cerebral artery, resulting in in-
farctions2,7. Common findings on imaging are abnormal
meningeal enhancement in the basal cisterns, hydro-
cephalus, and vascular complications2. Hydrocephalus
may occur in the early or latent stage of the disease even
after commencement of anti-TB drugs, and its manage-
ment may influence prognosis. Hydrocephalus encoun-
tered in TB meningitis can be broadly divided into two
types: communicating type, which is common, secondary
to an obstruction of the basal cisterns by inflammatory
exudates and obstructive type, which is less common and
either secondary to a focal parenchymal lesion causing
mass effect or due to the entrapment of a part of the ven-
tricle by granulomatous ependymitis2.
The typical analysis of cerebrospinal fluid with CNS
TB demonstrates a moderate lymphocytosis, moderately
elevated protein levels, and hypoglycorrachia. As such,
the CNS profile of CNS TB mimics the profiles of a large
list of both infectious and noninfectious processes that
affect the CNS. The predominance of neutrofils in some
cases likely represents an earlier stage of infection, which,
over the course of days to weeks, will convert to a pre-
dominantly lymphocitic profile22,23. CSF can also demon-
strate the presence of acid-fast bacilli. Mycobacterium tu-
berculosis complex can be identified specifically by DNA
probe or by nucleic acid amplification test24,25. Non-inva-
sive imaging modalities, such as computed tomography
scan and magnetic resonance imaging are routinely used
in the diagnosis of neurotuberculosis.
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Fig. 1. Normotensive hydrocephalus on multi-slice
computed tomography.
Treatment for all forms of CNS TBC should consist of
4 drugs (isoniasid, rifampicin, pyrasinamid, ethambutol)
for 2 mouths followed by 2 drugs (isoniasid, rifampicin)
for at least 10 months26. Studies show that adjunctive
corticosteroids decreases mortality27.
Tuberculous meningoencephalitis in presented pa-
tient was considered on the basis of clinical presentation,
laboratory findings (hyponatraemia) cerebrospinal fluid
studies, radiological findings (hydrocephalus on MSCT
and MRI of the brain), and history of orchiepididymitis of
unknown origin one year earlier, together with informa-
tion that the patient originated from Kosovo where inci-
dence of tuberculosis is still high. Subsequently, acid-fast
bacilli (AFB) staining on samples obtained after orchiec-
tomy a year ago was performed, revealing AFB. Anti-tu-
berculosis therapy is still in course. This is the second
case of tuberculous meningoencephalitis with the same
disease pattern (i.e. tuberculous orchiepididymitis – me-
ningoencephalitis) in our Department, and this fact was
crucial for the presumptive diagnosis and urgent treat-
ment of TB CNS. The former case was described five
years ago28. We point out that in case of meningoence-
phalitis, hydrocephalus and orchiepididymitis, tubercu-
losis must be taken into consideration.
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TUBERKULOZNI ORHIEPIDIDIMITIS, MENINGOENCEFALITIS I HDROCEFALUS
S A @ E T A K
Tuberkulozni je meningoencefalitis (TBM) rijedak, no ozbiljan, ~esto fatalan oblik aktivne tuberkuloze i na njega
otpada oko 1% svih slu~ajeva tuberkuloze. Rana dijagnoza i lije~enje klju~ni su u smanjenju pobola i smrtnosti. Prika-
zan je slu~aj TBM-a u {ezdesetogodi{njaka. Na TBM se posumnjalo na temelju klini~ke slike, laboratorijskih nalaza
(hiponatremija), analize cerebrospinalnog likvora, radiografskih nalaza (hidrocefalus na vi{eslojnoj spiralnoj kompju-
teriziranoj tomografiji mozga) te podatka o preboljelom orhiepididimitisu nepoznate etiologije godinu dana ranije, a
uzev{i u obzir da je bolesnik podrijetlom s Kosova gdje je u~estalost tuberkuloze jo{ uvijek visoka. Mycobacterium tuber-
culosis je izoliran iz cerebrospinalnog likvora na Lowenstein-Jensenovoj podlozi potvrdiv{i dijagnozu TBM-a. Nakna-
dno su i u uzorcima tkiva dobivenima nakon orhiektomije godinu dana ranije na|eni acidorezistentni bacili. Antituber-
kulozna terapija je u tijeku. Ovo je drugi slu~aj tuberkuloznog meningoencefalitisa s jednakim obrascem bolesti (tj.
tuberkulozni epididimitis-meningoencefalitis) u na{oj Klinici {to je bilo klju~no u postavljanju radne dijagnoze i za-
po~injanju hitnog lije~enja. Prvi je slu~aj opisan prije pet godina.
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